QuidelOrtho Corp reported an insider purchase this week as President and Chief Executive Officer Brian J. Blaser acquired 10,540 shares of the company's common stock on February 13, 2026. The total value of the transaction was $248,660, with an average price of $23.5921 per share. Executed trades in the block ranged between $23.4200 and $23.9400 a share.
At the time of this transaction, the $1.66 billion diagnostic healthcare company was trading near $24.38. That market price sits slightly above a fair value estimate and follows a substantial 18.4% decline in QuidelOrtho's share price over the prior week.
Following the purchase, Blaser directly holds 25,142 shares and additionally retains 40,073 shares indirectly through a trust. The purchase represents a material personal investment by the company chief, while the firm itself faces continuing financial challenges: QuidelOrtho was not profitable over the last twelve months.
Analysts, however, see a potential improvement ahead. Consensus forecasts call for earnings of $2.17 per share for fiscal year 2026, suggesting a possible return to profitability on a per-share basis if expectations materialize.
Quarterly results and market reaction
QuidelOrtho's fourth-quarter 2025 results display a mix of outcomes. Adjusted earnings per share came in at $0.46, below the $0.51 that analysts had anticipated, representing a 9.8% negative surprise versus expectations. Revenue for the quarter totaled $724 million, exceeding the $701 million forecast and producing a 3.28% positive surprise on the top line. Those results paint a nuanced picture for the company, with revenue strength offset by an earnings shortfall.
The company has not announced any mergers or acquisitions in the current updates. Likewise, there were no reported analyst upgrades or downgrades accompanying the recent filings, leaving the market to weigh the mixed earnings and sales figures alongside the insider purchase.
Research and subscriber resources
A subscription research service provides six additional insights and a comprehensive Pro Research Report on QuidelOrtho, which is listed among a broad coverage set of U.S. equities available to subscribers. These resources may offer investors further context on valuation, operations, and analyst expectations.
Investors and market participants will likely consider the insider purchase in the context of recent price volatility, the company’s lack of trailing profitability, and analyst forecasts for fiscal 2026.